Despite the trust between physicians and patients, some physicians believe another prescription drug crisis may arise.
Most primary care physicians, corresponding to about 62%, fear the opioid drug crisis will transition to a new prescription drug crisis and about 72%, worry that chronic pain patients will turn to illicit drugs if they do not have access to prescription opioids, according to a new Health Trends report from Quest Diagnostics.
The report, Drug Misuse in America 2019: Physician Perspectives and Diagnostics Insights on the Evolving Drug Crisis, provides insights into physicians' concerns about patient misuse of prescription and other drugs, as compared with results of objective lab data.
Within the lab data, half of test results of patients prescribed an opioid or other controlled medication, about 51% show signs of drug misuse and one in four, or 24% show signs of potentially dangerous drug mixing.
The first-of-its kind report includes findings from a new online survey of 500 U.S. primary care physicians, conducted by The Harris Poll, and commissioned by Quest Diagnostics in consultation with Center on Addiction, about the use of controlled prescribed medications, such as opioids, amphetamines, benzodiazepines and illicit drugs.
It comapres the survey responses with an analysis of more than 4.4 million de-identified drug monitoring test results ordered by physicians for patients prescribed controlled medications and performed by Quest Diagnostics between 2011 and 2018.
These two data sets reveal the contrast between physician expectations about patient drug use and the evolution of the drug epidemic and actual patient behavior, as revealed by objective lab data, amid a national drug crisis that claimed an estimated 68,500 lives last year.
Related: Four Ways Health Execs Can Help Patients Recover from Addiction
"Quest Diagnostics undertook this research so that we could provide insights into the evolving drug crisis and the potential role of physicians' perspectives about their patients in drug misuse and use disorders," says report co-author Harvey W. Kaufman, MD, senior medical director and director, Health Trends Research Program, Quest Diagnostics. "We found that primary care physicians, who are on the front lines of the drug epidemic, are well-intentioned but under-prepared and may miss some of the drug misuse risks affecting their patients, as reflected by our nationally representative laboratory data."
Among the key findings:
Physicians may be overconfident in their ability to recognize prescription drug misuse:
Drug mixing, the most prevalent form of drug misuse, is underestimated by physicians:
Gabapentin is emerging as an alternative pain therapy to opioids-just as misuse increases:
Gabapentin, an anticonvulsant that can be used to relieve neuropathic pain, has recently been classified as a controlled substance in some states, the study says.
"A vast majority of physicians recognize the need for more tools to prevent opioid drug misuse and substance use disorders, and that is why many are tightening opioid prescribing and turning to gabapentin as an alternative," says report co-author and practicing pain specialist Jeffrey Gudin, MD, senior medical advisor of Prescription Drug Monitoring, Quest Diagnostics. "While gabapentin may not have opioids' addictive potential, it can exaggerate euphoric effects when combined with opioids or anxiety medications. This drug mixing is dangerous."
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More